Download Application Note:
Combining Fixed-bed Bioreactors and Resin-free Affinity Purification for Streamlined, Low-cost Lentiviral Manufacturing
In the field of cell and gene therapy, lentiviral vector (LVV) manufacturing faces significant challenges, including high costs, scalability issues, and sensitivity to degradation. Traditional workflows often involve complex transfection processes, costly clarification steps, and inefficient downstream purification, limiting accessibility and commercial viability.
This Application note is related to the information that is available in our free on-demand webinar presented by Isolere Bio and Univercells Technologies exploring how the combination of scale-X™ fixed bed bioreactors (from Univercells Technologies) and IsoTag™ LVV purification reagent (from Isolere Bio) revolutionizes LVV production. Discover how this integrated approach enhances productivity, reduces costs, and simplifies manufacturing for preclinical and clinical applications.